Educational Dose Illustrator

INVEGA TRINZA® (paliperidone palmitate) For Schizophrenia

See Important Safety Information throughout this document.

The Educational Dose Illustrator can be used to visualize how dosing affects paliperidone plasma concentrations following administration of:

INVEGA SUSTENNA® for:

INVEGA TRINZA® for:

View this website online by scanning the QR code or visiting the URL below http://www.EducationalDoseIllustrator.com

Transition from Any Other Long‑Acting Injectable (LAI) Antipsychotic to INVEGA SUSTENNA® to INVEGA TRINZA®

Graph

Key

  1. Representative example of a long-acting, once-monthly injectable antipsychotic medication at steady-state administered every 4 weeks (scroll left to view prior doses).

  2. Consistent with the INVEGA TRINZA® Prescribing Information:

    • Clinically stable patients entering the INVEGA TRINZA® long-term maintenance study who were being treated with any other LAI product were transitioned to 234 mg of the INVEGA SUSTENNA® administered in the deltoid muscle in place of the next scheduled injection.
    • Per the INVEGA TRINZA® Prescribing Information, a clinically stable patient on a long-acting injectable antipsychotic (other than RISPERDAL CONSTA®) should receive the first INVEGA SUSTENNA® dose in the deltoid muscle. Additional INVEGA SUSTENNA® doses may be administered in either the deltoid or gluteal muscle. Please note for this illustrative example only, once the second INVEGA SUSTENNA® site of injection is selected, it will remain constant for all subsequent INVEGA SUSTENNA® doses.
    • Please note: Since the LAI antipsychotic and INVEGA SUSTENNA® are not related molecules, the total plasma concentration line only reflects the paliperidone concentration. The previous LAI antipsychotic concentration gradually decreases until it is eliminated.

    INVEGA TRINZA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+TRINZA-pi.pdf]
    INVEGA SUSTENNA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf]

  3. Consistent with the INVEGA TRINZA® Prescribing Information:

    • INVEGA TRINZA® is to be used only after INVEGA SUSTENNA® (1-month paliperidone palmitate extended-release injectable suspension) has been established as adequate treatment for at least four months.
    • Adjust the INVEGA SUSTENNA® dose (78 mg, 117 mg, 156 mg, or 234 mg) according to efficacy/tolerability needs of the patient.
    • In order to establish a consistent maintenance dose, it is recommended that the last two doses of INVEGA SUSTENNA® be the same dosage strength before starting INVEGA TRINZA®.

    INVEGA TRINZA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+TRINZA-pi.pdf]
    INVEGA SUSTENNA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf]

  4. Consistent with the INVEGA TRINZA® Prescribing Information:

    • Initiate INVEGA TRINZA® when the next INVEGA SUSTENNA® dose is scheduled with an INVEGA TRINZA® dose based on the previous INVEGA SUSTENNA® dose, using the equivalent 3.5-fold higher dose as shown in table below.

    INVEGA TRINZA® Doses for Adult Patients Adequately Treated with INVEGA SUSTENNA®

    If the Last Dose of INVEGA SUSTENNA® is:

    Initiate INVEGA TRINZA® at the Following Dose:

    78 mg

    273 mg

    117 mg

    410 mg

    156 mg

    546 mg

    234 mg

    819 mg

    Conversion from the INVEGA SUSTENNA® 39 mg dose was not studied.

    • INVEGA TRINZA® should be administered every 3 months.
    • Please note for this illustrative example only, once the INVEGA TRINZA® site of injection is selected, it will remain constant for all subsequent INVEGA TRINZA® doses.

    INVEGA TRINZA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+TRINZA-pi.pdf]
    INVEGA SUSTENNA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf]

Dose Information

Graph Information

^ Back to Top

Transition to INVEGA TRINZA® from Any Other LAI Antipsychotic (Any Other LAI Antipsychotic to INVEGA SUSTENNA® to INVEGA TRINZA®)

Consistent with the INVEGA TRINZA® Prescribing Information:

INVEGA TRINZA® Doses for Adult Patients Adequately Treated with INVEGA SUSTENNA®

If the Last Dose of INVEGA SUSTENNA® is:

Initiate INVEGA TRINZA® at the Following Dose:

78 mg

273 mg

117 mg

410 mg

156 mg

546 mg

234 mg

819 mg

Conversion from the INVEGA SUSTENNA® 39 mg dose was not studied.

INVEGA TRINZA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+TRINZA-pi.pdf]
INVEGA SUSTENNA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf]

Please Confirm

×

Thank you for visiting the Educational Dose Illustrator.

By clicking "Continue" below, you will be taken to a website where our Privacy Policy does not apply. You are solely responsible for your interactions with such websites.

We encourage you to read the Privacy Policy of every website you visit. Please view our Privacy Policy at your convenience.

Continue Cancel